eTable 1. ICD-9-CM Codes for Mental Health Diagnoses
eTable 2. Covariate Results of Proportional Hazards Regression Models Regarding Risk of Suicide Death for 2014 VHA PC-PTSD Screens—Positive vs Negative PC-PTSD Screens
eTable 3. Covariate Results of Proportional Hazards Regression Models Regarding Risk of Suicide Death for 2014 VHA PC-PTSD Screens—PC-PTSD Individual Item Responses
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Cooper SA, Szymanski BR, Bohnert KM, Sripada RK, McCarthy JF. Association Between Positive Results on the Primary Care–Posttraumatic Stress Disorder Screen and Suicide Mortality Among US Veterans. JAMA Netw Open. 2020;3(9):e2015707. doi:10.1001/jamanetworkopen.2020.15707
Are positive results on the Primary Care–Posttraumatic Stress Disorder Screen associated with an increase in the risk of suicide mortality among veterans receiving care in the US Veterans Health Administration system and, if so, does this risk decrease over time?
In this cohort study of 1 552 581 veteran patients receiving care in the US Veterans Health Administration system who were followed up through 2016, analyses of 1 693 449 screens for posttraumatic stress disorder administered in 2014 indicated a statistically significant 58% increase in the risk of suicide mortality at 1 day after a positive screening result. This risk of suicide mortality decreased over time.
The study's findings indicate that additional mental health and suicide risk assessment may be warranted after a patient receives a positive result on the Primary Care–Posttraumatic Stress Disorder Screen.
Suicide rates are higher among veterans compared with nonveterans, and the prevalence of posttraumatic stress disorder (PTSD) is higher among veterans compared with the general adult population in the US. To date, no study has examined the association between PTSD screening results and suicide mortality among veterans.
To examine whether veterans receiving care in the US Veterans Health Administration (VHA) health system who had positive results on the Primary Care–Posttraumatic Stress Disorder Screen (PC-PTSD) had a greater risk of suicide mortality compared with those who had negative results and to assess whether such risk decreased over time.
Design, Setting, and Participants
Multivariable proportional hazards regression models were used to evaluate suicide mortality risk through December 31, 2016, among a cohort of veterans who received the PC-PTSD in the VHA health system. The VHA administers the PC-PTSD to patients nationwide, and screening results are routinely documented in the VHA Corporate Data Warehouse. The PC-PTSD includes 4 questions regarding PTSD symptoms, to which patients respond with either a positive (yes) or negative (no) answer. All patients who completed the PC-PTSD in 2014 and who did not have a diagnosis of PTSD in the year before screening were included in the analysis. A score of 3 or 4 on the PC-PTSD indicated a positive result, and a score of 0, 1, or 2 indicated a negative result. Data collection and analyses were performed from November 13, 2018, to June 18, 2019.
Primary Care–Posttraumatic Stress Disorder Screen (PC-PTSD).
Main Outcomes and Measures
Suicide mortality risk, as assessed through data obtained from the US Veterans Affairs/Department of Defense Mortality Data Repository.
A total of 1 693 449 PC-PTSDs were completed by 1 552 581 individual veteran patients in 2014. Most of the patients were White (73.9%), married (52.2%), male (91.1%), 55 years or older (62.5%), and had completed only 1 PC-PTSD (92.1%). In multivariable analyses, positive PC-PTSD results (ie, total scores of 3 or 4) were associated with a 58% increase in the risk of suicide mortality at 1 day after screening (hazard ratio [HR], 1.58; 95% CI, 1.19-2.10) and a 26% increase in the risk of suicide mortality at 1 year after screening (HR, 1.26; 95% CI, 1.07-1.48). A positive response on item 4 (“felt numb or detached from others, activities, or your surroundings”) of the PC-PTSD was associated with a 70% increase in suicide mortality risk at 1 day after screening (HR, 1.70; 95% CI, 1.27-2.28).
Conclusions and Relevance
Positive PC-PTSD results, and specifically reports of feeling numb or detached, were associated with increases in the risk of suicide mortality. These associations decreased over time. The findings of this study can inform interpretation of PC-PTSD responses and suggest the importance of recent improvements made to the VHA suicide risk assessment.
Posttraumatic stress disorder (PTSD) is one of the signature wounds of war among veterans who served in the conflicts in Afghanistan and Iraq. The estimated lifetime prevalence of PTSD among veterans is 11% to 12%,1 nearly double that of the general adult population in the US, which is 6% to 8%.2-4 Posttraumatic stress disorder is associated with an increased risk of morbidity5-7 and mortality.8 Among veterans, PTSD is associated with increased impairment in psychosocial functioning, decreased health-associated quality of life,9 and increased mortality.10-16
Veterans also have an increased risk of suicide.17 Suicide prevention is the first clinical priority of the US Department of Veterans Affairs. Posttraumatic stress disorder is associated with increases in suicidal ideation and suicide attempts.18,19 Findings regarding the association between PTSD and suicide mortality among veterans have differed across studies, in part depending on the covariates included in the analyses. In general, analyses without adjustments for mental health comorbidities have reported positive associations between a diagnosis of PTSD and suicide risk,12-14,16 while analyses with adjustments for mental health comorbidities have observed negative associations.16,20-23
Previous studies have typically relied on PTSD diagnoses reported in medical records; however, patients may experience clinically important PTSD symptoms without receiving a diagnosis,24 and PTSD symptoms may fluctuate over time.25 Therefore, it may be informative to evaluate the suicide mortality risk associated with self-reported PTSD symptoms among veterans without an established PTSD diagnosis. Recent studies have identified positive associations between PTSD symptoms and both suicidal ideation and suicidal behaviors26-32; however, to our knowledge, no study has examined whether veteran-reported PTSD symptoms are associated with the risk of suicide mortality.
The US Veterans Affairs/Department of Defense Clinical Practice Guidelines recommend periodic PTSD screening, including annual assessments during the first 5 years after military separation and every 5 years thereafter. The US Veterans Health Administration (VHA) primarily uses the Primary Care–Posttraumatic Stress Disorder Screen (PC-PTSD) for its annual PTSD screening. This screen was based on criteria from the Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) and was developed to quickly identify patients with PTSD who receive primary care in the VHA heath system.33 The PC-PTSD includes only 4 items, facilitating its administration during routine care, which most often occurs in primary care settings.
To our knowledge, no study has examined the association between PTSD symptoms and suicide mortality. Information regarding suicide mortality risk after the administration of the VHA PC-PTSD may inform veteran suicide prevention activities and provide new information regarding the association between PTSD symptoms and suicide. We hypothesized that positive PC-PTSD results (ie, total scores of 3 or 4) would be associated with suicide mortality. Because PTSD symptoms may fluctuate over time, we further hypothesized that associations between reports of symptoms and suicide mortality risk would decrease over time.
Using the VHA Corporate Data Warehouse, we identified 1 837 114 completed PC-PTSD screens in 2014. Data regarding vital status and cause of death were obtained from the joint US Veterans Affairs/Department of Defense Mortality Data Repository. Screens were excluded if data on vital status and cause of death were unavailable or if the recorded date of death was before or on the date of the PC-PTSD. Additional exclusion criteria included having no record of a VHA inpatient or outpatient encounter on the screening date, administration of the PC-PTSD at a facility outside of the 50 US states and the District of Columbia, documented death in Puerto Rico or the Virgin Islands, missing or invalid data on patient age (ie, ages <18 years or >115 years), and nonveteran status as indicated by VHA patient records and Department of Defense personnel records. The analyses were conducted as part of ongoing VHA operations and program evaluation and were approved by the Veterans Affairs Office of Mental Health and Suicide Prevention. This report followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.
A total of 4 items are included in the PC-PTSD. Each item is a response to the question, “In your life, have you ever had any experience that was so frightening, horrible, or upsetting that”: (1) “in the past month, you have had nightmares about it or thought about it when you did not want to?”; (2) “tried hard not to think about it or went out of your way to avoid situations that reminded you of it?”; (3) “were constantly on guard, watchful, or easily startled?”; and (4) “felt numb or detached from others, activities, or your surroundings?” Patients respond to each item with an answer of yes (considered a positive response) or no (considered a negative response). The PC-PTSD has been reported to have high diagnostic validity in primary care and mental health care settings.33-35
For the main analysis, we limited the cohort of screens to those administered to veterans without a PTSD diagnosis (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 309.81) associated with a VHA inpatient stay or outpatient encounter in the 365 days before each PC-PTSD was administered. These criteria identified 1 693 449 total screens administered to 1 552 581 individual patients.
Suicide mortality was measured from 1 day after each PC-PTSD administration date through December 31, 2016. Data on patient mortality and cause of death were obtained from the Mortality Data Repository, and suicide death was defined by International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes U03, X60 to X84, and Y87.0.
Most covariate data were collected from the Corporate Data Warehouse and the VHA National Patient Care Database. Patient age and sex were obtained from the Mortality Data Repository and, if missing, from medical records. Data on suicide attempts were collected from the Veterans Affairs Suicide Prevention Applications Network36 database as well as medical records. At the patient level, risk factor data collected were age, sex, service-connected disability status for PTSD, marital status, race, and mental health diagnoses. Age was assessed on January 1, 2014. The service-connected disability compensation program provides tax-free monthly benefits to veterans for disabilities that were incurred or aggravated during military service.37 Service-connected disability status for PTSD was defined as an effective date of disability status that occurred before the date of the patient’s initial PC-PTSD in 2014. The presence of other mental health diagnoses was assessed in the 365 days before and including the initial PC-PTSD administration date in 2014. Specific ICD-9-CM codes for identifying the presence of mental health diagnoses are available in eTable 1 in the Supplement.
At the screening level, 6 indicator variables were created to categorize the types of care patients received on each PC-PTSD administration date: primary care services through the Primary Care–Mental Health Integration program, primary care services outside of the Primary Care–Mental Health Integration program, specialty mental health care services, other outpatient services, inpatient mental health stay, and other inpatient stay. Variables were created to capture emergency department or inpatient mental health stays as well as the number of emergency department visit days and inpatient mental health bed-days in the 365 days before the screening date. An indicator variable was created for the presence of a documented suicide attempt in the 365 days before and including the screening date when the patient had an ICD-9-CM diagnosis code of E95.0-E95.8 in the medical records or when a suicide attempt was documented in the Suicide Prevention Applications Network database. Indicator variables were also created to record prescription fills for antipsychotic, antidepressant, benzodiazepine, mood stabilizer, and anxiolytic or sedative medications in the 365 days before and including the screening date.
Responses for each PC-PTSD were prepared for analysis in 3 ways. First, an indicator variable was created to record whether each PC-PTSD had a positive (total score of 3 or 4)33 or negative (total score of 0, 1, or 2) result. Second, each of the 4 items was treated as an individual indicator based on whether that item received a positive or negative response. Third, each screen was assigned a score (ranging from 0-4) for the total number of items with positive responses.
For descriptive analyses, frequencies were calculated, both overall and by suicide mortality status, for all variables among 1 552 581 patients. In bivariate analyses, the responses on the patient’s initial PC-PTSD in 2014 were examined by suicide mortality status through December 31, 2016. Fisher exact tests and χ2 tests were used to assess the differences in proportions, and Kruskal-Wallis tests were used to evaluate differences in means. Suicide rates per 100 000 person-years were calculated at the patient level by multiplying the number of observed suicides by 100 000, then dividing that value by the number of person-years at risk from the day after each patient’s initial PC-PTSD in 2014 until death or December 31, 2016, whichever occurred first.
In the proportional hazards regression analyses, each PC-PTSD screen was used as the unit of analysis. The patient’s time at risk began the day after the PC-PTSD was administered and ended at death or on December 31, 2016, whichever occurred first. We used partially conditional proportional hazards regression models38 and controlled for nonsuicide mortality as a competing risk. By treating each screen as the unit of analysis, the models were conditioned on the baseline covariates (age, sex, PTSD service connection, marital status, race, and mental health diagnoses) but not on the time-varying covariates (PC-PTSD responses, types of care received, and presence of a previous suicide attempt).
Five main proportional hazards regression models were used to examine suicide mortality risk by comparing positive (total score of 3 or 4) vs negative (total score of 0-2) PC-PTSD results, with adjustment for varying levels of covariates. An additional set of models were used, in which each item on the PC-PTSD was included as the main effect. Because we hypothesized that the suicide mortality risk among those with positive PC-PTSD results would be higher during the time closer to the screening date, we included an interaction term between the main effect and time in all models. Covariates were included in the models to adjust for potential confounding variables in the association between PC-PTSD responses and suicide mortality.39,40 We adjusted for covariates using a stepped process to better understand the associations between the covariates, the focal indicator, and the outcome.
Covariance sandwich estimators were used to adjust for the nested nature of the data, with screens nested within individuals and screens of individual patients nested within VHA facilities. The proportional hazards assumption was evaluated for all models. A supplemental post hoc trend analysis was performed in which PC-PTSD scores were treated as a continuous variable.
Three sensitivity analyses were conducted for both sets of models. First, to examine how screening results were associated with the risk of suicide mortality regardless of a previous diagnosis of PTSD, we analyzed all models by using a larger cohort of 1 790 355 patients, in which we retained screens that were associated with a PTSD diagnoses in the previous 365 days. Second, to eliminate overlapping time at risk, we analyzed all models by censoring time at risk at each patient’s subsequent PC-PTSD administration. Third, to assess whether the elimination of repeated PC-PTSD administrations would alter the observed associations, we restricted the analyses to 1 552 581 initial PC-PTSD screens in 2014. None of the sensitivity analyses produced results that substantially differed from those observed in the main analysis. All tests were 2-sided and unpaired, with a significance threshold of α = .05. Data collection and analyses were conducted from November 13, 2018, to June 18, 2019. Data analyses were performed using SAS software, version 9.4 and the SAS Enterprise Guide, version 7.1 (SAS Institute Inc).
Among 1 552 581 patients included in the analysis, 73.9% were White, 52.2% were married, 91.1% were male, and 62.5% were 55 years or older (Table 1). Most patients (92.1%) in the cohort received only 1 PC-PTSD in 2014, and the maximum number of screens received per person was 23. The number of days at risk ranged from 1 to 1095 (ie, 3 years), with a median time at risk of 904 days (interquartile range, 809-997 days) for all screens. A total of 1423 patients (0.1%) died by suicide within the follow-up period. The unadjusted suicide mortality rate was 37.6 deaths per 100 000 person-years.
A total of 46 759 PC-PTSD screens were excluded from the analysis. Excluded screens were less likely to have had positive results compared with included screens (9.1% vs 13.8%, respectively; χ2 P < .001). Among those excluded, 42 948 screens were able to be linked to a patient’s vital status. An analysis of those patients indicated that they were more likely to die by suicide through December 31, 2016, compared with patients whose screens were included (0.3% vs 0.1%, respectively; P < .001).
Among 166 685 patients with positive initial PC-PTSD results in 2014, 88.5% were male, 64.7% were White, and 34.8% were 55 years or older. Among 1 385 896 patients with negative initial PC-PTSD results, 91.5% were male, 75.1% were White, and 65.9% were 55 years or older. In the bivariate analysis, among patients with positive initial PC-PTSD results, 0.13% died by suicide compared with 0.09% of patients with negative initial PC-PTSD results (P < .001).
In the analysis unadjusted for covariates, a positive PC-PTSD result was associated with a 90% increase in the risk of suicide mortality at 1 day after screening (hazard ratio [HR], 1.90; 95% CI, 1.44-2.52) compared with a negative result (model 1 in Table 2). This risk decreased throughout the follow-up period (β for interaction = −0.0006; P = .04), which was up to 1095 days. The unadjusted suicide-specific survival probabilities are shown in the Figure. In the analysis adjusted for all covariates, a positive PC-PTSD result was associated with a 58% increase in the risk of suicide mortality at 1 day after screening (HR, 1.58; 95% CI, 1.19-2.10), and this risk decreased over time (β for interaction = −0.0006; P = .03) (model 5 in Table 2). At 30 days after screening, the HR for a positive PC-PTSD result was 1.55 (95% CI, 1.18- 2.04). At 365 days after screening, the HR was 1.26 (95% CI, 1.07-1.48), which represented a 26% increase. The HR at 475 days after screening was nonsignificant (HR, 1.17; 95% CI, 0.99-1.38). Covariate results are available in eTable 2 in the Supplement.
In the unadjusted analysis examining each PC-PTSD item separately, a positive (yes) response to item 4 (“felt numb or detached from others, activities, or your surroundings”) was associated with a 117% increase in the risk of suicide mortality at 1 day after screening (HR, 2.17; 95% CI, 1.61-2.92), and this risk decreased over time (β for interaction = −0.0007; P = .009) (model 1 in Table 3). In the analysis adjusted for all covariates, a positive response to item 4 was associated with a 70% increase in the risk of suicide mortality at 1 day after screening (HR, 1.70; 95% CI, 1.27-2.28), and this risk also decreased over time (β for interaction = −0.0007; P = .007) (model 5 in Table 3). At 30 days after administration of the PC-PTSD, the HR for suicide mortality associated with a positive response to item 4 was 1.67 (95% CI, 1.26-2.21). At 365 days after screening, the HR was 1.31 (95% CI, 1.07-1.59), and the HR at 460 days after screening was nonsignificant (HR, 1.22; 95% CI, 0.99-1.48). Covariate results are available in eTable 3 in the Supplement. A post hoc test for trend revealed a 14% increase in suicide mortality risk for each unit increase in the PC-PTSD score (baseline HR, 1.14; 95% CI, 1.05-1.23; β for interaction = −0.0002; P = .01) (model 5 in Table 4).
Among patients who received PC-PTSD screens through the VHA health system in 2014, positive PC-PTSD results were associated with an increased risk of suicide mortality through 1 year after screening. We observed a significant dose-response pattern in the association between PC-PTSD score and suicide mortality, with greater risk observed as the number of positive responses to PC-PTSD items increased. We found a positive association between PTSD symptoms and suicide mortality even in analyses that were controlled for several mental health diagnoses. This pattern differed from that of previous studies examining PTSD diagnoses and suicide mortality.16,20-23 Our findings indicate that veterans who receive positive results on the PC-PTSD have an increased risk of suicide mortality. These findings may inform treatment decisions and support the need for continued improvement of suicide risk assessment.
We note that our sample consisted of patients who did not have a formal diagnosis of PTSD yet remained at an increased risk of suicide mortality. A PTSD diagnosis requires the presence of symptoms across 4 domains: reexperiencing, avoidance, negative alterations in cognition and mood, and hyperarousal. These symptoms must persist for more than 1 month.41 However, the presence of subthreshold PTSD symptoms may indicate suicide risk regardless of whether a patient qualifies for a formal diagnosis.42 In the absence of a PTSD diagnosis, a positive PC-PTSD result may indicate subthreshold symptoms that suggest a patient has an increased risk of suicide mortality. Patients with a positive PC-PTSD result may also have met the full diagnostic criteria for PTSD, which had not been detected until the time of screening.43 As a consequence, in lieu of waiting for a formal diagnosis, it may be important to consider initiating suicide risk assessment strategies for patients with positive responses on the PC-PTSD. Another reason to use and incorporate the PC-PTSD into suicide risk assessment strategies is that, unlike a medical records diagnosis, the PC-PTSD asks a patient about PTSD symptoms experienced within the past month. The symptom severity of PTSD may fluctuate daily,25 and this fluctuation has been linked to adverse health outcomes.44 Although further research is warranted, findings from the present analysis suggest that the PC-PTSD might be a better indicator of immediate suicide mortality risk than a static diagnosis obtained from the medical record. Future research is needed to examine differences in suicide mortality risk among those who receive a formal PTSD diagnosis after administration of the PC-PTSD.
Additional risk was associated with a positive response to item 4 (“felt numb or detached from others, activities, or your surroundings”). This symptom has been associated with suicidal ideation in previous research.26,28,30,45,46 A positive response to item 4 may indicate feelings of social isolation or thwarted belongingness, which may be one of the most important factors in suicidal desire, as described by the interpersonal theory of suicide.47,48 This finding highlights the need to improve social support systems and encourage engagement in meaningful activities, which may not only reduce PTSD symptoms but potentially help to mitigate the risk of suicide.
In 2018, the VHA implemented a new strategy for risk assessment that included the addition of 1 measure to the PC-PTSD. This measure, item 9 from the Patient Health Questionnaire, asks patients about suicidal ideation. Positive responses to that item have been associated with an increase in suicide risk.49,50 The VHA requires additional risk evaluation for patients with positive responses to item 9. The findings of the present study raise the possibility that positive PC-PTSD results may also be associated with greater suicide mortality risk. As more current mortality data become available, future analyses will assess risk using the expanded instrument to evaluate this issue and inform ongoing VHA health system suicide prevention activities.
This study has several study limitations. We examined PC-PTSD data available in VHA medical records, and these data may not be generalizable to other populations. Although the sample included all screens coded in the administrative data for 2014, we may not have captured every PC-PTSD administered within the VHA health care system in 2014. We noted in the Results section that patients with excluded screens had an increased risk of suicide mortality. Excluding their screens may have inflated the study results, as excluded screens were less likely to have had positive overall results compared with included screens. In addition, we did not assess depressive symptoms, which may be associated with suicide mortality risk, at the time of PC-PTSD administration. The PC-PTSD has been updated based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition51; this update, the PC-PTSD-5, has been used in the VHA health care system since 2018. Future research is needed to examine the associations between PC-PTSD-5 results and suicide among patients receiving care in the VHA system.
To our knowledge, this is the first study to examine the association between positive PC-PTSD results and suicide mortality. Positive PC-PTSD results, and specifically positive responses on items that describe feeling numb or detached, were associated with an increase in the risk of suicide mortality, which decreased over time. The PC-PTSD may identify distinct risks that are not identified by other assessment procedures used in the VHA or other health systems.
Accepted for Publication: June 23, 2020.
Published: September 3, 2020. doi:10.1001/jamanetworkopen.2020.15707
Correction: This article was corrected on October 15, 2020, to fix an error in the Methods section.
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Cooper SA et al. JAMA Network Open.
Corresponding Author: Samantha A. Cooper, MPH, Serious Mental Illness Treatment Resource and Evaluation Center, Office of Mental Health and Suicide Prevention, Department of Veterans Affairs, 2800 Plymouth Rd, Building 16, Floor 2, Ann Arbor, MI 48109 (email@example.com).
Author Contributions: Ms Cooper had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Cooper, Bohnert, Sripada, McCarthy.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Cooper, Bohnert, McCarthy.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Cooper, Szymanski, Bohnert.
Obtained funding: McCarthy.
Supervision: Bohnert, McCarthy.
Conflict of Interest Disclosures: Dr Bohnert reported receiving grants from the US Department of Veterans Affairs Health Services Research and Development Service during the conduct of the study. Dr Sripada reported receiving grants from the US Department of Veterans Affairs Health Services Research and Development Service outside the submitted work. No other disclosures were reported.
Funding/Support: This study was supported by grants CDA 11-245 (Dr Bohnert) and CDA 15-251 (Dr Sripada) from the US Department of Veterans Affairs Health Services Research and Development Service. The work was conducted as part of the quality improvement operations of the Serious Mental Illness Treatment Resource and Evaluation Center, Office of Mental Health and Suicide Prevention, US Department of Veterans Affairs.
Role of the Funder/Sponsor: The Office of Mental Health and Suicide Prevention at the US Department of Veterans Affairs reviewed the manuscript but had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Talya Peltzman, MPH, of the Serious Mental Illness Treatment Resource and Evaluation Center, Office of Mental Health and Suicide Prevention, US Department of Veterans Affairs provided assistance with data collection and analysis for this manuscript. Ms Peltzman did not receive additional compensation for her contributions.
Create a personal account or sign in to: